Neuron23
PrivateLast Round
Grant
Jun 17, 2026
Total Funding Raised
$346M
Company Overview
Neuron23 is a biotechnology company that develops AI-driven drug discovery platforms and precision medicines for genetically defined neurological and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuron23 Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Neuron23 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 17, 2026 | ||||
| Series D | Jun 24, 2025 | ||||
| Series C | Mar 30, 2022 | ||||
| Series B | Dec 16, 2020 | ||||
| Series A | Dec 16, 2020 | ||||
Series A | Oct 18, 2018 |
Key People
Founding team and executive leadership
Neuron23 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D, Series B |
| Surveyor Capital | Series C, Series B |
| SoftBank Investment Advisers | Series D, Series C |
| Westlake Village BioPartners | Series D, Series C, Series B, Series A |
| Cowen Private Investments | Series C, Series B |
| Perceptive Advisors | Series C, Series B |
| TD Securities | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 2, 2025
NEULARK trial targets LRRK2 gene overactivity.
- Jun 25, 2025
Partnered with Sano Genetics for subject referrals and participant identification.
Neuron23 Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neuron23's valuation, stock price, and market status.